Monitor FDA feedback on LX2006 pivotal trial protocol, expected in Q2 2026. Positive response would de-risk the program and likely drive upside. The company's strong cash position reduces near-term financing risk.
Price Chart
Executive Summary
Lexeo Therapeutics reported Q1 2026 results with a net loss of $20.2M ($0.25 per share), narrowing from $32.7M ($0.99 per share) in Q1 2025 and beating consensus estimates of $0.29 loss per share by 13.8%. Cash stood at $227.6M, providing runway into 2028. Pipeline progress continues with LX2006 pivotal trial protocol under FDA review and LX2020 data expected later in 2026.
Key Financial Metrics
Key Facts
- Net loss narrowed to $20.2M ($0.25/share) from $32.7M ($0.99/share) YoY
- EPS of $0.25 beat consensus of $0.29 by 13.8%
- Cash, cash equivalents, and investments: $227.6M, providing runway into 2028
- Awaiting FDA feedback on SUNRISE-FA2 pivotal study protocol for LX2006
Financial Impact
Quarterly cash burn reduced to ~$19M (net loss + non-cash items) from ~$31M in Q1 2025, improving cash runway visibility
Risk Factors
- FDA may delay or request changes to the SUNRISE-FA2 trial design
- Clinical trial enrollment or data could disappoint
- Dilution risk from future equity financings if cash is depleted faster than expected
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-215674 |
| Document: lxeo-20260511.htm | 0001193125-26-215674 |
| Document: lxeo-ex99_2.htm | 0001193125-26-215674 |
| Document: 0001193125-26-215674-index-headers.html | 0001193125-26-215674 |
| Document: 0001193125-26-215674-index.html | 0001193125-26-215674 |
| Document: 0001193125-26-215674.txt | 0001193125-26-215674 |
| 8-K Data (Synthetic) | 0001193125-26-215674 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | SC 13G | $2.74 $3.02 | ▲ +10.22% | ▲ +11.37% | $2.78 (+1.28%) |
Sep 22, 2026 5w ago | 8-K | $4.07 $3.42 | ▼ −15.97% | ▼ −14.78% | $2.78 (−31.82%) |
Aug 12, 2026 10w ago | 8-K | $4.87 $5.37 | ▲ +10.27% | ▲ +10.71% | $2.78 (−43.02%) |
Aug 12, 2026 10w ago | Press Release | $4.87 $5.37 | ▲ +10.27% | ▲ +10.71% | $2.78 (−43.02%) |
Jul 1, 2026 16w ago | Insider Cluster | $4.69 $5.05 | ▲ +7.68% | ▲ +6.75% | $2.78 (−40.83%) |
Jun 17, 2026 18w ago | Press Release | $4.93 $4.70 | ▼ −4.67% | ▼ −3.00% | $2.78 (−43.71%) |
Jun 15, 2026 19w ago | 8-K | $4.65 $5.04 | ▲ +8.39% | ▲ +9.77% | $2.78 (−40.32%) |
Jun 12, 2026 19w ago | Institutional Cluster | $4.37 $4.93 | ▲ +12.81% | ▲ +12.14% | $2.78 (−36.50%) |
May 20, 2026 22w ago | Insider Cluster | $5.23 $5.14 | ▼ −1.72% | ▼ −3.57% | $2.78 (−46.94%) |
May 11, 2026 24w ago | 8-K | $6.12 $4.71 | ▼ −23.04% | ▼ −22.95% | $2.78 (−54.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers